Dataset from A Multicenter Randomized Study Evaluating Dosing Regimens for Treatment With Intravitreal Ranibizumab Injections in Subjects With Macular Edema Following Retinal Vein Occlusion

This was a Phase IV multicenter, randomized, open-label study, with masking of the vision examiner, of the efficacy and safety of intravitreal ranibizumab 0.5 mg in subjects with macular edema following Branch Retinal Vein Occlusion (BRVO) or Central Retinal Vein Occlusion (CRVO).

本研究为IV期多中心随机开放标签临床试验，设置视力检查设盲，旨在评估0.5mg玻璃体内注射雷珠单抗用于分支视网膜静脉阻塞（BRVO）或中心视网膜静脉阻塞（CRVO）继发黄斑水肿受试者的有效性与安全性。